Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

NEW HAVEN, Conn. (WTNH) — A new Yale-led study published Thursday identified a new target for treating the most common form of cancer in children and young adults, B-cell acute lymphoblastic leukemia ...

Survival disparities in patients with acute lymphoblastic leukemia: A focus on young adult and adolescent patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Oncaspar (pegaspargase) is a long-acting prescription injection medicine used for people with a type of blood cancer known as acute lymphoblastic leukemia (ALL). It is also approved specifically for ...

Investigators evaluated children with acute lymphoblastic or acute myeloid leukemia to identify racial/ethnic and neighborhood disparities in acute kidney injury.

September is Leukemia and Lymphoma Awareness Month. An estimated 1,629,474 people in the United States (US) are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes ...

In most cases, acute lymphoblastic leukemia (ALL) manifests as a de novo malignancy in previously healthy people. Risk factors for developing ALL include age older than 70 years and genetic disorders, ...

Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a higher risk version ...

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed ...

Asparlas (calaspargase pegol-mknl) is a long-acting prescription injection medicine used for people with a certain type of blood cancer known as acute lymphoblastic leukemia (ALL). It is approved in ...